Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

APLM

Apollomics Inc

May 13 • 04:00PM ET

0.3498

Dollar change -0.0221
Percentage change -5.94	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: CNCR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.80	Insider Own	27.31%	Shs Outstand	89.50M	Perf Week	-16.69%
Market Cap	31.31M	Forward P/E	-	EPS next Y	-0.92	Insider Trans	0.00%	Shs Float	65.05M	Perf Month	-37.46%
Income	-172.60M	PEG	-	EPS next Q	-0.17	Inst Own	0.83%	Short Float	0.19%	Perf Quarter	-50.01%
Sales	-	P/S	-	EPS this Y	71.77%	Inst Trans	0.56%	Short Ratio	0.69	Perf Half Y	-57.70%
Book/sh	8.69	P/B	0.04	EPS next Y	-40.46%	ROA	-	Short Interest	0.12M	Perf Year	-92.09%
Cash/sh	0.42	P/C	0.83	EPS next 5Y	-	ROE	-	52W Range	0.36 - 6.45	Perf YTD	-63.75%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-98.15%	ROI	-415.90%	52W High	-94.58%	Beta	1.43
Dividend TTM	-	Quick Ratio	3.84	Sales past 5Y	0.00%	Gross Margin	-	52W Low	-3.13%	ATR (14)	0.05
Dividend Ex-Date	-	Current Ratio	2.95	EPS Y/Y TTM	-4466.07%	Oper. Margin	0.00%	RSI (14)	24.60	Volatility	8.16% 10.35%
Employees	-	Debt/Eq	0.11	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	4.25
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	-1366.67%	Payout	-	Rel Volume	2.43	Prev Close	0.37
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Mar 28 BMO	Avg Volume	177.24K	Price	0.35
SMA20	-22.62%	SMA50	-38.09%	SMA200	-80.18%	Trades		Volume	429,996	Change	-5.94%

May-08-24 04:05PM	Apollomics Announces Private Placement Financing and Addition to Board of Directors (GlobeNewswire)
Apr-25-24 08:30AM	Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene (GlobeNewswire)
Apr-10-24 07:00AM	Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Apr-02-24 08:00AM	Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) -7.93%
Mar-28-24 07:00AM	Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results (GlobeNewswire) +23.97%
08:00AM	Loading…
Mar-26-24 08:00AM	Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024 (GlobeNewswire)
Mar-04-24 10:18AM	Apollomics Names Matthew Plunkett as Chief Financial Officer (Exec Edge)
07:00AM	Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer (GlobeNewswire)
Feb-07-24 07:00AM	Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) +13.33%
Jan-19-24 04:15PM	Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire)
Jan-17-24 04:30PM	Apollomics to Participate in a Fireside Chat at the B. Riley Securities 2024 Virtual Oncology Conference (GlobeNewswire)
Jan-03-24 06:52PM	Apollomics Completes Patient Enrollment for Phase 3 Trial of Leukemia Treatment (Exec Edge)
07:00AM	Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia (GlobeNewswire)
Jan-02-24 04:30PM	Apollomics to Present at the 2024 Biotech Showcase (GlobeNewswire)
Dec-07-23 01:01PM	Apollomics Presents Data from Phase 2 Clinical Trials of Lung Cancer Medication (Exec Edge) -8.14%
07:00AM	Loading…
Dec-04-23 07:00AM	Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation (GlobeNewswire) -15.12%
Nov-29-23 07:30AM	Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference (GlobeNewswire)
Nov-28-23 07:00AM	Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC) (GlobeNewswire)
Nov-16-23 08:30AM	Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer (GlobeNewswire)
Oct-31-23 08:30AM	Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation (GlobeNewswire) -11.11%
Oct-27-23 08:03AM	Why Is Apollomics (APLM) Stock Up 113% Today? (InvestorPlace) +51.76%
Oct-26-23 08:50AM	Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion (GlobeNewswire) -26.23%
Oct-24-23 09:35AM	Apollomics Treating MET-Altered Cancers: KUNPENG Trial Results (Exec Edge) -5.37%
Oct-23-23 08:30AM	Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75% (GlobeNewswire) -43.24%
Oct-16-23 06:55PM	Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023 (GlobeNewswire)
Sep-28-23 04:17PM	Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Sep-06-23 07:00AM	Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Apr-11-23 08:30AM	Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium (GlobeNewswire) -14.00%
Mar-31-23 08:01AM	Qiming Venture Partners Welcomes Apollomics' Successful IPO on Nasdaq (PR Newswire) -17.69%
Mar-30-23 08:00AM	Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq (GlobeNewswire) +171.97%
07:30AM	Loading…
07:30AM	Apollomics Co-Founder & CEO Guo-Liang Yu on Treating Cancer, Going Public (IPO-Edge.com)

Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company was founded by Liang Yu Guo and Sanjeev Redkar in 2015 and is headquartered in Foster City, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

APLM

Apollomics Inc

Upgrade your FINVIZ experience